Health
16 Oct 2026
Gilead and Vir partner to develop next‑generation T‑cell engagers for solid tumours
The two companies will share an upfront payment and future milestones to create three dual‑masked T‑cell therapies.
Read moreTopic
#Vir Biotechnology
1 story